Renal Involvement in Hospitalized Children With COVID-19

NCT04788394 | Completed DMC

• 1 other identifier: MRC01-21-089
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

Covid-19 is an important human and animal pathogen, it mostly causes respiratory and gastrointestinal symptoms. Clinical features range from a common cold to severe diseases such as severe acute respiratory distress syndrome, bronchitis, pneumonia, multi-organ failure, and even death. It seems to be less commonly affecting children and to cause fewer symptoms and less severe disease in this age group compared with adults. Clinicians have observed many extrapulmonary manifestations of COVID-19, as hematologic, cardiovascular, renal, gastrointestinal and hepatobiliary, endocrinologic, neurologic, ophthalmologic, and dermatologic systems can all be affected. This retrospective study that will be conducted at Hamad General Hospital in Qatar, aims to determine the renal involvement in all pediatric patients who were hospitalized with COVID-19 from March 1, 2020, to January 1, 2021.

Conditions

Acute Kidney Injury; Covid19; Renal Dysfunction; Coronavirus Infection; AKI; Pediatric Kidney Disease; Renal Insufficiency

Outcome Measures

Primary Outcomes (1)

• determine the prevalence of renal dysfunction in hospitalized children with COVID19 in Qatar.

  explore and describe the rate of renal symptoms and signs, and severity in pediatric patients admitted to the hospital with COVID 19 in Qatar . The relation between severity of disease and age , weight , gender ,and nationality of participants .

  1 year

Interventions

data review OTHER

In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included: * Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia). * Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\]. * Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI. to determine:

data comparing OTHER

In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory-confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included: * Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia). * Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\]. * Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI. to determine:

Eligibility Criteria

• Age: 1 Day - 14 Years
• Sex: all
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

This retrospective review of electronic medical records from the pediatric division, Hamad General hospital in Doha, Qatar, will include all hospitalized children (0-14 years) who were diagnosed with COVID-19 between March 1, 2020, to January 1, 2021. Data collection will be done by co-investigators for all patients.

You may qualify if:

• All pediatric patients with COVID-19 were admitted to Hamad Hospital from (0 to 14) years, using the electronic medical records (Cerner), over that time period (from March 1, to January 1, 2021), with one of the following:
• Proteinuria: (≥1+) on dipstick analysis.
• Hematuria: ≥ 5 RBC/HPF.
• Sterile Pyuria: ≥ 5 WBC/HPF or ≥10 WBC/mm3 with negative urine culture (44).
• Hypernatremia :\> 145meq/l.
• Hyponatremia: \< 135 meq/l.
• Hypokalemia :\< 3.5meq/l.
• Metabolic acidosis (ph \<7.35).
• Elevated serum creatinine :\> upper limit of reference interval (ULRI) values.
• Elevated serum urea: \> 7 mmol/l.
• Urine specific gravity (SG) \<1.003.

You may not qualify if:

• \* Patient with previous chronic kidney diseases.

Sponsors & Collaborators

• Hamad Medical Corporation: lead

Study Sites (1)

Hamad General corporation

Doha, 3050, Qatar

Location

MeSH Terms

Conditions

Acute Kidney Injury; COVID-19; Renal Insufficiency; Coronavirus Infections

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Mahmoud Alhandi Omar Helal

  Hamad Medical Corporation

  PRINCIPAL INVESTIGATOR

• Mahmoud Helal

  Hamad Medical Corporation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 7, 2021
• First Posted: March 9, 2021
• Study Start: March 1, 2021
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2021
• Last Updated: July 25, 2023

Record last verified: 2021-03

Locations

QA (1)